Compare First Solar, Inc. (FSLR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? First Solar, Inc. trades at $177.22 (market cap $19.25B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: First Solar, Inc. is far larger — about 19.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FSLR | MRVI | |
|---|---|---|
Market Cap | $19.25B | $977.37M |
Volume | 2,086,427 | 2,742,564 |
Sector | Energy | Health |
52-Week High | $318.30 | $9.00 |
52-Week Low | $172.11 | $2.83 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $17.71B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $186.60, up 3.83% today, but remains in a bearish technical trend with resistance near $190. The company reported strong revenue growth to $5.22 billion in 2025 and a net income margin of 32.47%, though it missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit against competitors and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
FSLR presents a value opportunity with a low P/E of 11.5 and analyst consensus price target of $269, but faces risks from solar industry headwinds and technical bearish signals. Earnings beats in recent quarters support fundamentals, yet political and financing challenges could limit near-term upside.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
